![The Asian Pacific Association for the Study of the Liver [APASL]](https://www.apasl.info/wp-apasl/wp-content/themes/apasl/images/header/img_apasl_logo.png){kind=logo}
GUIDELINES: Australian best practice recommendations for transjugular intrahepatic portosystemic shunt (TIPS) in portal hypertension: a consensus statementhttps://link.springer.com/article/10.1007/s12072-025-11023-x ORIGINAL ARTICLE: Tirzepatide versus SGLT2 inhibitors for MASLD: a multi-institutional propensity score-matched cohort studyhttps://link.springer.com/article/10.1007/s12072-025-11021-z ORIGINAL ARTICLE: TACE and tyrosine kinase inhibitors with or without PD-1 inhibitors as first-line therapy for intermediate-advanced HCC: a multicenter real-world cohort studyhttps://link.springer.com/article/10.1007/s12072-026-11052-0 ORIGINAL ARTICLE: Risk factors of adult recipient survival beyond 20 years since liver transplantation: retrospective cohort studyhttps://link.springer.com/article/10.1007/s12072-025-11029-5
